Stay updated on ACTT: Remdesivir for Severe COVID-19 Clinical Trial
Sign up to get notified when there's something new on the ACTT: Remdesivir for Severe COVID-19 Clinical Trial page.

Latest updates to the ACTT: Remdesivir for Severe COVID-19 Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe page now shows Revision: v3.6.3, replacing the previous v3.6.0. This indicates a patch-level update to the page's revision history without altering the core content of the study details.SummaryDifference0.0%

- Check15 days agoChange Detected- Added a new publication reference (Lin et al.) to the study record. This article discusses evaluating treatment efficacy in hospitalized COVID-19 patients and its applications to Adaptive COVID-19 Treatment Trials, expanding the record's related literature.SummaryDifference0.0%

- Check22 days agoChange DetectedThe page now shows 'No longer looking for participants' to signal enrollment is closed, and it adds guidance sections such as 'How to Read a Study Record', 'Common Questions', and 'How to Join a Study', while updating the revision stamp to v3.6.0 and adjusting the Intervention/Treatment heading.SummaryDifference0.3%

- Check29 days agoChange DetectedThe page now displays Revision: v3.5.5, replacing the previous Revision: v3.5.4. This indicates an updated version of the associated document on the page.SummaryDifference0.0%

- Check50 days agoChange DetectedA new revision tag v3.5.4 was added and the previous tag v3.5.3 was removed, indicating an update to the page's revision history rather than substantive changes to the study details.SummaryDifference0.0%

- Check72 days agoChange DetectedThe page now shows an updated ClinicalTrials.gov interface revision (from v3.5.2 to v3.5.3). This reflects a minor platform/version update rather than a change to the study record content.SummaryDifference0.0%

Stay in the know with updates to ACTT: Remdesivir for Severe COVID-19 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ACTT: Remdesivir for Severe COVID-19 Clinical Trial page.